Nivethika Jeyakumar

Nov 14, 2024 | jamanetwork.com | Ziv Harel |Nivethika Jeyakumar |Graham Smith |Joel Ray

Introduction Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are increasingly used to treat diabetes, heart failure, and chronic kidney disease.1 Approximately 80% of individuals taking SGLT2is also receive statins.2 A 2020 case report3 described the onset of rhabdomyolysis after initiation of canagliflozin in a patient taking rosuvastatin.